Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 6/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962002 | 1.00 | LMNA (0.51) | LMNAMAPK1STAT3KCNH2TP53 | |
| SCHEMBL9961998 | 1.00 | LMNA (0.51) | LMNAMAPK1STAT3KCNH2TP53 | |
| SCHEMBL8403577 | 0.96 | TP53 (0.50) | LMNAMAPK1STAT3KCNH2TP53 | |
| SCHEMBL764166 | 0.93 | TP53 (0.45) | LMNAKCNH2TP53MAPTSMN1; SMN2 | |
| SCHEMBL9962107 | 0.93 | LMNA (0.46) | LMNAMAPK1STAT3TP53MAPT | |
| SCHEMBL764337 | 0.92 | LMNA (0.48) | LMNAMAPK1STAT3TP53MAPT | |
| SCHEMBL8404306 | 0.91 | TP53 (0.46) | LMNAKCNH2TP53MAPTSMN1; SMN2 | |
| SCHEMBL765014 | 0.91 | TP53 (0.44) | LMNAKCNH2TP53MAPTSMN1; SMN2 | |
| SCHEMBL14236421 | 0.91 | TP53 (0.43) | LMNAKCNH2TP53MAPTSMN1; SMN2 | |
| SCHEMBL8404298 | 0.91 | TP53 (0.43) | LMNAKCNH2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | LMNA 3640/4885MAPK1 2724/4885STAT3 598/4885 |
| US-20090209521-A9 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | LMNA 3640/4885MAPK1 2724/4885STAT3 598/4885 |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | LMNA 4243/4885MAPK1 2363/4885STAT3 140/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | LMNA 1455/4885MAPK1 3121/4885STAT3 857/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | LMNA 3199/4885MAPK1 2092/4885STAT3 148/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | LMNA 3985/4885MAPK1 3418/4885STAT3 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.